EUCTR2004-000591-13-IT进行中（未招募）不适用
Phase II prospective randomized multicenter study of Folfiri versus Folfiri Cox-2 inhibitor versus Folfiri followed by Cox-2 inhibitor in the first-line treatment of colo-rectal cancer
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 159
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- 未提供
研究者
相似试验
已完成
2 期
Prospective randomized multicenter phase II study of pulmonalfiliae metastases (poor-prognosis) in clear cell renal cell carcinoma + / - adjuvant Sunitinibtherapie than 1 year - SMAT - AN 20/04kidney cancerC64C78.0Malignant neoplasm of kidney, except renal pelvisSecondary malignant neoplasm of lungDRKS00003518niversitätsklinikum Essen10
已完成
2 期
Prospective randomized multicenter phase II trial of low-dose decitabine (DAC) administered alone or in combination with the histone deacetylase inhibitor valproic acid (VPA) and all-trans retinoic acid (ATRA) in patients > 60 years with acute myeloid leukemia who are ineligible for induction chemotherapyC92.9Myeloid leukaemia, unspecifiedDRKS00000733niversitätsklinikum Freiburg204
进行中（未招募）
1 期
Clinical trial of low-dose decitabine (DAC) administered alone or in combination with the valproic acid (VPA) and all-trans retinoic acid (ATRA) in patients > 60 years with acute myeloid leukemia who are ineligible for standard chemotherapyEUCTR2009-009916-33-DEniversity Medical Center Freiburg200
进行中（未招募）
1 期
A prospective, multicenter, randomized PHASE II clinical trial of enzalutamide treatment to decrease the morbidity in patients with Corona virus disease 2019 (COVID-19)EUCTR2020-002027-10-SEorrlands universitetssjukhus600
进行中（未招募）
不适用
A Phase II, randomised, multicentre study to evaluate the efficacy and safety of pazopanib in combination with pemetrexed versus cisplatin plus pemetrexed, as first-line therapy in subjects with stage IIIB/IV non-small cell lung cancerHistologically- or cytologically-confirmed diagnosis of non-predominantly squamous cell Stage IIIBwet (with confirmed malignant pleural effusion) or Stage IV NSCLCMedDRA version: 9.1Level: LLTClassification code 10029521Term: Non-small cell lung cancer stage IIIBMedDRA version: 9.1Level: LLTClassification code 10029522Term: Non-small cell lung cancer stage IVEUCTR2008-002144-42-DKGlaxoSmithKline R&D Limited150